Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
270 results about "Cardiac hypertrophy" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Cardiac hypertrophy. enlargement of the heart coincident with an increase in muscle mass; an indication of response to an increase in load which may or may not be associated with disease. It is an expression of cardiac compensation but some of the cardiac reserve has been lost.
Cardiovascular disease diagnostic and therapeutic targets
InactiveUS20050130136A1Reduce cardiovascular riskReduce riskMicrobiological testing/measurementDisease diagnosisRisk strokeTreatment goals
This invention pertains to methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, the invention relates to isolated molecules that can be used to diagnose and / or treat cardiovascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure.
Owner:THE BRIGHAM & WOMENS HOSPITAL INC
Methods of use of inhibitors of phosphodiesterases and modulators of nitric oxide, reactive oxygen species, and metalloproteinases in the treatment of peyronie's disease, arteriosclerosis and other fibrotic diseases
ActiveUS20050085486A1Increasing NO levelReduce expressionBiocidePharmaceutical delivery mechanismFemale Sexual Arousal DisorderCyclase
The present methods and compositions are of use for treatment of conditions involving fibrosis, such as Peyronie's disease plaque, penile corporal fibrosis, penile veno-occlusive dysfunction, Dupuytren's disease nodules, vaginal fibrosis, clitoral fibrosis, female sexual arousal disorder, abnormal wound healing, keloid formation, general fibrosis of the kidney, bladder, prostate, skin, liver, lung, heart, intestines or any other localized or generalized fibrotic condition, vascular fibrosis, arterial intima hyperplasia, atherosclerosis, arteriosclerosis, restenosis, cardiac hypertrophy, hypertension or any condition characterized by excessive fibroblast or smooth muscle cell proliferation or deposition of collagen and extracellular matrix in the blood vessels and / or heart. In certain embodiments, the compositions may comprise a PDE-4 inhibitor, a PDE-5 inhibitor, a compound that elevates cGMP and / or PKG, a stimulator of guanylyl cyclase and / or PKG, a combination of a compound that elevates cGMP, PKG or NO with an antioxidant that decreases ROS, or a compound that increases MMP activity.
Owner:LOS ANGELES BIOMEDICAL RES INST AT HARBOR UCLA MEDICAL CENT
Methods and compositions for treating conditions caused by excessive calcium influx in cells using optically pure (-) amlodipine
Methods are disclosed utilizing the optically pure (-) isomer of amlodipine. This compound is a potent drug for the treatment of hypertension while avoiding the concomitant liability of adverse effects associated with the racemic mixture of amlodipine. The (-) isomer of amlodipine is also useful for the treatment of angina and such other conditions as may be related to the activity of (-) amlodipine as a calcium channel antagonist such as cerebral ischemia, cerebral disorders, arrhythmias, cardiac hypertrophy, coronary vasospasm, myocardial infarction, renal impairment and acute renal failure, without the concomitant liability of adverse effects associated with the racemic mixture of amlodipine.
Owner:SEPACOR INC
IL-33 in the treatment and diagnosis of diseases and disorders
This invention relates to methods and compositions for the treatment and diagnosis of cardiac diseases and disorders, such as cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis and heart failure. The invention also relates to methods and compositions for the treatment of fibrosis-related diseases as well as methods and compositions for reducing apoptosis, increasing ST2L signaling, decreasing NF-κB activation, decreasing IκBα phosphorylation, decreasing P38MAPK phosphorylation, decreasing JNK phosphorylation, decreasing reactive oxygen species generation, decreasing macrophage infiltration and / or decreasing the expression of hypertrophic genes. More specifically, the invention relates to IL-33 and / or soluble ST2 inhibiting agents for use in the methods and compositions provided.
Owner:THE BRIGHAM & WOMEN S HOSPITAL INC
Agents for treating cardiopathy
ActiveUS20090220500A1Improve the situationSuppressing left ventricular remodelingAntibody ingredientsImmunoglobulinsCardiac echoLeft ventricular size
The present inventors investigated the effects of anti-IL-6 receptor antibodies on improving the condition of infarcted areas in myocardial infarction, and on suppressing left ventricular remodeling after myocardial infarction. As a result, the administration of anti-IL-6 receptor antibodies significantly suppressed the increase of MPO activity in the infarcted area and suppressed myocardial MCP-1 expression in both the infarcted area and the non-infarcted area. Furthermore, echocardiography and histological examinations revealed that cardiac hypertrophy is also suppressed.
Owner:CHUGAI PHARMA CO LTD
IL1RL-1 as a cardiovascular disease marker and therapeutic target
InactiveUS7655415B2High expressionReduce riskMicrobiological testing/measurementDisease diagnosisVascular diseaseRisk stroke
This invention pertains to methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, the invention relates to isolated molecules that can be used to diagnose and / or treat cardiovascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure.
Owner:THE BRIGHAM & WOMEN S HOSPITAL INC
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
Compositions and methods are disclosed for stimulating or inhibiting angiogenesis and / or cardiovascularization in mammals, including humans. Pharmaceutical compositions are based on polypeptides or antagonists thereto that have been identified for one or more of these uses. Disorders that can be diagnosed, prevented, or treated by the compositions herein include trauma such as wounds, various cancers, and disorders of the vessels including atherosclerosis and cardiac hypertrophy. In addition, the present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
Owner:GENENTECH INC
Inhibition of TRP channels as a treatment for cardiac hypertrophy and heart failure
InactiveUS20050182011A1Improve athletic abilityProlonged dilationBiocidePeptide/protein ingredientsHeart diseaseCalcineurin phosphatase
The present invention provides methods of treating and preventing cardiac hypertrophy and heart failure. MEF-2, NF-AT3, calcineurin, MCIP, and Class II HDACs have been shown to have a major role in cardiac hypertrophy and heart disease, and inhibition of many of these factors or the pathways mediated by these factors has been shown to have a beneficial, anti-hypertrophic effect. The present invention provides a link between these factors and the pathways they mediate through a family of non-voltage gated channels called TRP channels. The present invention further demonstrates that inhibitors of TRP channels can inhibit or treat heart failure and cardiac hypertrophy.
Owner:MYOGEN INC +1
Method for treating cardiovascular diseases using rho kinase inhibitor compounds
This invention is directed to methods of preventing or treating diseases or conditions associated with excessive cell proliferation, remodeling, inflammation, and vasoconstriction. Particularly, this invention is directed to methods of treating cardiovascular diseases or conditions such as stent restenosis and thrombosis, vascular thrombosis, cerebral vasospasm, atherosclerosis, systemic hypertension, cardiac hypertrophy, and sexual dysfunction. The method comprises identifying a subject in need of the treatment, and administering to the subject an effective amount of a novel Rho kinase inhibitor compound to treat the disease.
Owner:INSPIRE PHARMA
IL1RL-1 as a cardiovascular disease marker and therapeutic target
InactiveUS20060216755A1Reduce cardiovascular riskReduce riskMicrobiological testing/measurementDisease diagnosisVascular diseaseRisk stroke
This invention pertains to methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, the invention relates to isolated molecules that can be used to diagnose and / or treat cardiovascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure.
Owner:THE BRIGHAM & WOMEN S HOSPITAL INC
Organic Compounds
InactiveUS20090076062A1Avoid actionReduce formationBiocideSenses disorderIntra ocular pressureCardiac fibrosis
Disclosed are δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amide compounds of formula (I)and the salts thereof, having renin-inhibiting properties. Also disclosed are pharmaceutical compositions comprising these compounds and methods of administering them for the treatment of hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, unstable coronary syndrome, diastolic dysfunction, chronic kidney disease, hepatic fibrosis, complications resulting from diabetes, such as nephropathy, vasculopathy and neuropathy, diseases of the coronary vessels, restenosis following angioplasty, raised intra-ocular pressure, glaucoma, abnormal vascular growth, hyperaldosteronism, cognitive impairment, alzheimers, dementia, anxiety states and cognitive disorders.
Owner:MAIBAUM JUERGEN KLAUS +2
Kit for testing and identifying genetic cardiac hypertrophy related gene mutation
The invention relates to a kit for detecting genetic cardiac hypertrophy related gene mutation samples, particularly to a product for detecting genetic cardiac hypertrophy related genes by a massively parallel sequencing platform technology. The method involved in the kit comprises: a) uniquely designing and preparing a capture probe, which is directed at all exon fragments of genes ACTC1, ACTN2, BRAF, CALR3, CASQ2, CSRP3, GLA, HRAS, JPH2, KRAS, LAMP2, LDB3, MAP2K1, MYBPC3, MYH6, MYH7, MYL2, MYL3, MYLK2, MYOZ2, PRKAG2, RAF1, SOS1, TCAP, TNNC1, TNNI3, TNNT2, TPM1, TTN, TTR, and VCL; b) designing unique joints with tag sequences; c) using universal primers to conduct PCR amplification on probe sequences; and d) designing unique operations for capture of mixed target fragments. The massively parallel sequencing platform prepared by the method and the kit has the advantages of high sample throughput, high efficiency, and easy operation, thus greatly reducing the sequencing testing cost.
Owner:康旭基因技术(北京)有限公司
Methods and compositions for treating cardiac dysfunctions
InactiveUS20090022729A1Treating and preventing hypertrophyBiocideDipeptide ingredientsCardiac dysfunctionProphylactic treatment
The present invention provides methods and pharmaceutical compositions for treating or preventing cardiac dysfunctions (e.g., cardiac hypertrophy, cardiac remodeling, or heart failure) in subjects who have or are likely to develop cardiomyopathies. Some of the methods are directed to therapeutic or prophylactic treatment of cardiac dysfunctions in subjects having undergone myocardial injuries such as cardiac ischemia / reperfusion or myocardial infarction. Typically, these methods comprising administering to the subjects a therapeutic composition comprising a compound which can specifically inhibit PAR1 mediated signaling or down-regulate the cellular level of PAR1.
Owner:THE SCRIPPS RES INST +1
Fused azole-pyrimidine derivatives
Owner:BAYER INTELLECTUAL PROPERTY GMBH +1
Fused azole-pyrimidine derivatives
The present invention relates to hovel fused azolepyrimidine derivatives, processes for preparing them and pharmaceutical preparations containing them. The fused azolepyrimidine derivatives of the present invention exhibit enhanced potency for phosphotidylinositol-3-kinase (PI3K) inhibition, especially for PI3K-γ inhibition and can be used for the prophylaxis and treatment of diseases associated with PI3K and particularly with PI3K-γ activity. More specifically, the azole derivatives of the present invention are useful for treatment and prophylaxis of diseases as follows: inflammatory and immunoregulatory disorders, such as asthma, atopic dermatitis, rhinitis, allergic diseases, chronic obstructive pulmonary disease (COPD), septic shock, joint diseases, autoixnmune pathologies such as rheumatoid arthritis, and Graves' disease, cancer, myocardial contractility disorders, heart failure, thromboembolism, ischemia, and atherosclerosis. The compounds of the present invention are also useful for pulmonary hypertension, renal failure, cardiac hypertrophy, as well as neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease, diabetes and focal ischemia, since the diseases also relate to PI3K activity in a human or animal subject.
Owner:BAYER INTELLECTUAL PROPERTY GMBH +1
Methods for treating myocardial infarction comprising administering an IL-6 inhibitor
ActiveUS8945558B2Improve the situationSuppressing left ventricular remodelingPeptide/protein ingredientsImmunoglobulins against cytokines/lymphokines/interferonsCardiac echoLeft ventricular size
The present inventors investigated the effects of anti-IL-6 receptor antibodies on improving the condition of infarcted areas in myocardial infarction, and on suppressing left ventricular remodeling after myocardial infarction. As a result, the administration of anti-IL-6 receptor antibodies significantly suppressed the increase of MPO activity in the infarcted area and suppressed myocardial MCP-1 expression in both the infarcted area and the non-infarcted area. Furthermore, echocardiography and histological examinations revealed that cardiac hypertrophy is also suppressed.
Owner:CHUGAI PHARMA CO LTD
Method for preventing or treating cardiac hypertrophy
InactiveUS20050276804A1Shorten the progressReduce severityBiocidePeptide/protein ingredientsRetinoidMammal
A method for treating or preventing cardiac hypertrophy in a mammal, comprising manipulating levels of RBP, retinoids, or an affiliated signaling and regulatory pathway in the mammal. Preferably, the method comprises reducing or inhibiting the level of RBP or retinoids or their signaling pathway, or an affiliated signaling pathway, via a dietary, genetic, protein-based, or pharmacologic approach, or a combination thereof. Also disclosed are pharmaceutical composition suitable for the method.
Owner:WISCONSIN ALUMNI RES FOUND +1
Identification of mirna profiles that are diagnostic of hypertrophic cardiomyopathy
InactiveUS20110160285A1High expressionHigh activityOrganic active ingredientsMicrobiological testing/measurementHypertrophic cardiomyopathyCell biology
Disclosed herein are a collection of miRNAs and genes whose expression is altered in hypertrophic cardiomyopathy. Accordingly, these miRNAs and genes, singly or in combination, are useful as molecular markers for diagnosis or prognosis of hypertrophic cardiomyopathy. The miRNAs and genes disclosed can also be therapeutic targets for cardiac hypertrophy. For example, agents such as miRNA mimics, miRNA inhibitors or siRNAs for a given miRNA or gene can be used to modulate the level of these molecules thereby inhibiting or preventing hypertrophic cardiomyopathy.
Owner:UNIV OF COLORADO THE REGENTS OF +1
Use of Rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy
The present invention is directed to a method for preventing or decreasing the incidence of or treating aneurysm or cardiac hypertrophy, comprising administering an effective amount of a rho-kinase inhibitor, such as fasudil, to a subject in need thereof.
Owner:SCHERING AG
MICRO-RNAs THAT MODULATE SMOOTH MUSCLE PROLIFERATION AND DIFFERENTIATION AND USES THEREOF
InactiveUS20090226375A1Regulate smooth muscleReduce neointima formationOrganic active ingredientsGenetic material ingredientsSmooth musclePercent Diameter Stenosis
The present invention relates to the identification of microRNAs that regulate smooth muscle cell proliferation and differentiation, including the miR-143 / miR-145 cluster. Methods of treating restenosis and neointima formation by increasing expression of miR-143 and / or miR-145 are disclosed. The present invention also relates to the identification of two microRNAs, miR-486 and miR-422a, that regulate cell survival in the heart. Methods of treating or preventing cardiac hypertrophy, heart failure, or myocardial infarction by increasing expression of miR-486 and / or miR-422a in heart tissue are also disclosed.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Pharmaceutical composition for preventing or remedying cardiac hypertrophy and cardiovascular disease caused thereby
InactiveUS20070135365A1Avoid signalingSuppress or reduce cardiac hypertrophyOrganic active ingredientsGenetic material ingredientsG protein-coupled receptorSignalling pathways
Compositions and methods for preventing or treating cardiac hypertrophy which inhibit the cardiac hypertrophy signal pathway mediated through G protein coupled receptors (GPCR) or epidermal growth factor (EGF) receptors. The present invention also relates to methods for screening active ingredients, and to animal models of cardiac hypertrophy.
Owner:OSAKA UNIV
IL-33 in the treatment and diagnosis of diseases and disorders
This invention relates to methods and compositions for the treatment and diagnosis of cardiac diseases and disorders, such as cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis and heart failure. The invention also relates to methods and compositions for the treatment of fibrosis-related diseases as well as methods and compositions for reducing apoptosis, increasing ST2L signaling, decreasing NF-κB activation, decreasing IκBα phosphorylation, decreasing P38MAPK phosphorylation, decreasing JNK phosphorylation, decreasing reactive oxygen species generation, decreasing macrophage infiltration and / or decreasing the expression of hypertrophic genes. More specifically, the invention relates to IL-33 and / or soluble ST2 inhibiting agents for use in the methods and compositions provided.
Owner:THE BRIGHAM & WOMEN S HOSPITAL INC
A micro-rna family that modulates fibrosis and uses thereof
ActiveUS20100285073A1Preventing pathologic hypertrophyHigh activityOrganic active ingredientsPeptide/protein ingredientsDiseaseMedicine
The present invention relates to the identification of a microRNA family, designated miR-29a-c, that is a key regulator of fibrosis in cardiac tissue. The inventors show that members of the miR-29 family are down-regulated in the heart tissue in response to stress, and are up-regulated in heart tissue of mice that are resistant to both stress and fibrosis. Also provided are methods of modulating expression and activity of the miR-29 family of miRNAs as a treatment for fibrotic disease, including cardiac hypertrophy, skeletal muscle fibrosis other fibrosis related diseases and collagen loss-related disease.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Micro-rnas that control myosin expression and myofiber identity
InactiveUS20100269183A1Inhibit expressionInhibitory activityOrganic active ingredientsGenetic material ingredientsDiseaseSkeletal muscle contraction
The present invention relates to the identification of two microRNAs, miR-499 and miR-208b, that repress fast skeletal muscle contractile protein genes. Expression of miR-499 and / or miR-208b can be used to repress fast fiber genes and activate slow fiber genes in the treatment of musculoskeletal disorders. Inhibition of miR-499 and / or miR-208b is proposed as a treatment for cardiac hypertrophy, myocardial infarction, and / or heart failure. Pharmaceutical compositions comprising antagonists and agonists of miR-499 and miR-208b function are also disclosed.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Phenothiazine kinesin inhibitors
Phenothiazine derivatives of formula (I) are disclosed. The compounds are inhibitors of the mitotic kinesin KSP and are useful in the treatment of cellular proliferative diseases, such as cancer, hyperplasias, restenosis, cardiac hypertrophy, immune disorders and inflammation.
Owner:CYTOKINETICS INC
Electrocardio ultrasonic signal fusion computed tomography imaging system and method
InactiveCN104068845ARealize synchronous acquisitionDiagnostic recording/measuringTomographyMyocarditisCardiac arrhythmia
The invention relates to a medical examination and diagnosis method and instrument, in particular to a multi-dimensional electrocardio ultrasonic signal fusion computed tomography imaging system and method based on anatomical orientation. A multi-dimensional ultrasonic cardiac structure and a perfusion image technology are further integrated on the basis of a multi-dimensional electrocardiosignal imaging system and method, and a novel non-invasive platform is provided for recording and evaluating the electro-mechanical signal characteristic and myocardial perfusion characteristic of heart. The method is a unique electrocardio-mechanical function and perfusion synchronized computed tomography imaging method based on anatomical orientation, and the technology is a non-invasive imaging technology for detecting transmural cardiac electrical activity information and mechanical signals. By adopting the medical examination and diagnosis method and instrument, the diagnosis of myocardial diseases such as cardiac hypertrophy, cardiomyopathy, myocardial infarction and myocarditis, the determination of the origin of arrhythmia, and the like can be enhanced, and a brand-new diagnosis and guide treatment tool is provided for rapid real-time diagnosis of heart diseases.
Owner:镇郁琼 +1
Micro-RNA family that modulates fibrosis and uses thereof
The present invention relates to the identification of a microRNA family, designated miR-29a-c, that is a key regulator of fibrosis in cardiac tissue. The inventors show that members of the miR-29 family are down-regulated in the heart tissue in response to stress, and are up-regulated in heart tissue of mice that are resistant to both stress and fibrosis. Also provided are methods of modulating expression and activity of the miR-29 family of miRNAs as a treatment for fibrotic disease, including cardiac hypertrophy, skeletal muscle fibrosis other fibrosis related diseases and collagen loss-related disease.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Phenothiazine kinesin inhibitors
Phenothiazine derivatives of formula (I) are disclosed. The compounds are inhibitors of the mitotic kinesin KSP and are useful in the treatment of cellular proliferative diseases, such as cancer, hyperplasias, restenosis, cardiac hypertrophy, immune disorders and inflammation.
Owner:CYTOKINETICS INC
Use of Inhibitors of the Ubiquitin Proteasome Pathway as a Method of Increasing Contractility of the Heart
InactiveUS20070015777A1Increase heart contractilityIncrease contractilityBiocideTripeptide ingredientsDegradative PathwayUbiquitin proteasome
The present invention describes novel uses for inhibitors of the ubiquitin proteasome degradative pathway. In particular it describes methods for improving cardiac function, increasing alpha myosin levels in the heart, and increasing SERCA levels in the heart. The invention also provides methods for treating cardiac hypertrophy through inhibiton of the ubiquitin proteasome.
Owner:MYOGEN INC
The use of kauranes compounds in the manufacture of medicament for treatment of cardiac hypertropy and pulmonary hypertension
The invention relates novel pharmaceutical use of kaurane compounds of formula (I) in treating and preventing cardiac hypertrophy and myocardium remodeling. The said compounds also can significantly ameliorate pulmonary hypertension and preventing vascular hypertrophy. The said compounds can also be used to suppress fibrosis and to treat erection dysfunction, neurological degenerations and other related diseases by modulating cGMP or cAMP signal pathway and / or by reducing reactive oxygen species (ROS). Wherein R1: hydrogen, hydroxyl or alkoxy. R2: carboxyl, carboxylate, acyl halides, aldehyde,methyl-hydroxyl, and ester, acylamide, acyl or ether group hydrolysable to carboxyl. R3, R4, R5, R6, R8: independently, oxygen, hydroxyl, methyl-hydroxyl, and ester or alkoxymethyl group hydrolysableto methyl-hydroxyl. R7: methyl, hydroxyl, and ester or alkoxymethyl hydrolysable to methyl-hydroxyl. R9: methylene or oxygen.
Owner:KEY PHARMA BIOMEDICAL INC +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com